Milmiga (Liraglutide)

Liraglutide activates the GLP‑1 receptor, which enhances glucose‑dependent insulin release, suppresses glucagon secretion, slows gastric emptying, and reduces appetite. These actions together lower blood glucose levels and promote weight loss.

The dose of Milmiga is individualized by the prescribing clinician. Typically, treatment starts with a low dose that is gradually increased based on therapeutic response and tolerability, following local prescribing guidelines.

Safety data for liraglutide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the Milmiga product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Milmiga (liraglutide) belongs to the GLP‑1 receptor agonist class, similar to semaglutide and dulaglutide. Compared with some alternatives, liraglutide has a shorter half‑life requiring daily injection, while others may be weekly. Efficacy for glycaemic control and weight loss is comparable, but individual response and tolerability can differ.

Milmiga must be stored in a refrigerator at 2‑8 °C. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to less than 30 °C for no more than 14 days.

Milmiga is given as a subcutaneous injection, typically in the abdomen, thigh, or upper arm. Patients should rotate injection sites to reduce local irritation and follow the prescriber’s instructions for dose titration and timing.

Serious risks include acute pancreatitis, thyroid C‑cell tumours (observed in animal studies), severe hypoglycaemia when combined with insulin or sulfonylureas, and acute renal injury. Prompt medical evaluation is required if symptoms such as severe abdominal pain, unexplained weight loss, or signs of low blood sugar occur.

Milmiga is contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, and in patients with known hypersensitivity to liraglutide or any excipients. Caution is also advised for those with severe gastrointestinal disease, pancreatitis history, or significant renal impairment.